papaverine
An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. Papaverine is a vasodilating agent. Papaverine is used for the treating certain conditions that are accompanied by smooth muscle spasms (eg, blood vessel, urinary, gallbladder, or intestinal spasm). Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is not paralyzed by Papaverine and still responds to drugs and other stimuli causing contraction. The antispasmodic effect is a direct one, and unrelated to muscle innervation. Papaverine is practically devoid of effects on the central nervous system. Papaverine relaxes the smooth musculature of the larger blood vessels, especially coronary, systemic peripheral, and pulmonary arteries. Papaverine is a potent, specific inhibitor of PDE10A. Papaverine for treatment of erectile dysfunction (ED) is excluded from coverage. — NCATS
Clinical trial activity
23 trials · 30 clinical orgs · 0 marketing orgs
Earliest trial started Aug 1, 2001 (NCT00080808)
Timeline
Indications
Approved for
Studied for
- Anesthesia · Phase 4
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Cognition Disorders · Early Phase 1
- Colorectal Neoplasms · Phase 1
- Coronary Vasospasm · Phase 4
- Delivery, Obstetric · Phase 4
- Erectile Dysfunction · Phase 2/Phase 3
- Gastroenteritis · Phase 3
- HIV Infections · Phase 2
- Kidney Neoplasms · Phase 4
- Lung Neoplasms · Phase 1
- Melanoma · Phase 1
- Pediatrics · Phase 4
- Prostatic Hyperplasia · Early Phase 1
- Prostatic Neoplasms · Phase 2
- Radial Artery · Phase 2
- Schizophrenia · Early Phase 1
Mechanism of action
- Phosphodiesterase 1INHIBITOR
Phosphodiesterase 1 inhibitor
Chemistry & pharmacology
SMILES
COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC- Mol. weight
- 339.39 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL19224 ↗
- WikipediaVL ↗
- NCATSDAA13NKG2Q ↗
- ChEMBLCHEMBL98123 ↗
- WikipediaPapaverine ↗
Also known as
- mesotina
- mesotina
- papaver hcl
- papaverin
- papaverine
- papaverine
- papaverine
- papaverine
- papaverine
- papaverine
- papaverine
- papaverine
- papaverine
- papaverine
- papaverine hcl
- papaverine hcl
- papaverine hcl
- papaverine hydrochloride
- papaverine hydrochloride
- papaverine hydrochloride
- pavabid
- pavabid
- trimix
- trimix
- vl#fia3-30
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07237880 | N/A | Apr 22, 2025 | Hillel Yaffe Medical Center |
| NCT06834126 | Phase 1 | Apr 7, 2025 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT06547437 | N/A | Sep 30, 2024 | Western Galilee Hospital |
| NCT06550232 | Phase 4 | Aug 11, 2024 | Western Galilee Hospital |
| NCT06919289 | N/A | Mar 7, 2024 | US Neuropathy Centers |
| NCT05861765 | Phase 2 | May 24, 2023 | Sun Yat-Sen University |
| NCT05759364 | N/A | May 15, 2023 | Galilee Medical Center, Western Galilee Hospital |
| NCT05136846 | Phase 1 | Dec 1, 2021 | Ohio State University |
| NCT04162834 | Phase 4 | Nov 21, 2019 | University of Ulsan |
| NCT03894904 | Phase 4 | Apr 1, 2019 | University of Texas at Houston |
| NCT04172558 | Phase 2/Phase 3 (Phase 3) | Mar 10, 2019 | Benha University |
| NCT03824327 | Phase 1 | Feb 7, 2019 | Ohio State University |
| NCT04030663 | Early Phase 1 (Phase 1) | Feb 5, 2019 | Cairo University |
| NCT03788083 | Phase 1 | Nov 12, 2018 | eTheRNA, Free University of Brussels |
| NCT03064282 | Early Phase 1 (Phase 1) | Apr 20, 2017 | Manchanda Medical Clinic |
| NCT02888756 | Phase 2 | Apr 4, 2017 | Asphalion, Badalona Hospital Germans Trias i Pujol, CR2O, Erasmus University Rotterdam, eTheRNA, Free University of Brussels, Institute of Tropical Medicine, Belgium, IrsiCaixa, Synapse bv, University of Barcelona |
| NCT02496845 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2015 | Technion University, VasoLead (2012) Ltd. |
| NCT02413645 | Phase 1 | Jun 1, 2015 | University of Barcelona |
| NCT01813955 | Early Phase 1 (Phase 1) | Jun 1, 2011 | University of Copenhagen |
| NCT02711241 | Phase 3 | Jun 1, 2010 | Hebrew University |
Organizations
Research & Development (30)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Free University of Brussels | Academic/Hospital | 3 | 1 | 2 | 2009 |
| Western Galilee Hospital | Academic/Hospital | 3 | 3 | 2 | 2023 |
| eTheRNA | For profit | 2 | 0 | 2 | 2017 |
| National Cancer Institute (NCI) | Government | 2 | 0 | 2 | 2001 |
| Ohio State University | Academic/Hospital | 2 | 2 | 1 | 2019 |
| University of Barcelona | Academic/Hospital | 2 | 1 | 2 | 2015 |
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 2 | 2001 |
| Asphalion | For profit | 1 | 0 | 1 | 2017 |
| Badalona Hospital Germans Trias i Pujol | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Benha University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Cairo University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| City of Hope National Medical Center | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| CR2O | For profit | 1 | 0 | 1 | 2017 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Galilee Medical Center | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Hebrew University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Hillel Yaffe Medical Center | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Institute of Tropical Medicine, Belgium | Academic/Hospital | 1 | 0 | 1 | 2017 |
| IrsiCaixa | Academic/Hospital | 1 | 0 | 1 | 2017 |